Clinical trials
Liver Cirrhosis, Biliary trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 7 |
| Active, not recruiting | 6 |
| Terminated | 5 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Intercept Pharmaceuticals | 7 |
| Gilead Sciences | 5 |
| Ipsen | 4 |
| GlaxoSmithKline | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Asociación Española para el Estudio del Hígado | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Calliditas Therapeutics AB | 1 |
| Calliditas Therapeutics Suisse SA | 1 |
| Enanta Pharmaceuticals, Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liver Cirrhosis, Biliary | 32 |
| Cholangitis, Sclerosing | 4 |
| Fibrosis | 4 |
| Pruritus | 4 |
| Cholestasis | 3 |
| Fatigue | 2 |
| Alagille Syndrome | 1 |
| Cholangitis | 1 |
| Digestive System Diseases | 1 |
| Genetic Diseases, Inborn | 1 |
Trials
Showing 51 to 32 of 32. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.